98%
921
2 minutes
20
Background: Atrial fibrillation (AF) screening was incorporated into an abdominal aortic aneurysm screening (AAA) program for New Zealand (NZ) Māori.
Methods: AF screening was performed as an adjunct to AAA screening of Māori men aged 60-74 years and women aged 65-74 years registered with primary health care practices in Auckland, NZ. Pre-existing AF was determined through coded diagnoses or medications in the participant's primary care record. Subsequent audit of the record assessed accuracy of pre-screening coding, medication use and clinical follow-up.
Results: Among 1,933 people successfully screened, the prevalence of AF was 144 (7.4%), of which 46 (2.4% of the cohort) were patients without AF coded in the medical record. More than half of these were revealed to be known AF but that was not coded. Thus, the true prevalence of newly detected AF was 1.1% (n=21). An additional 48 (2.5%) of the cohort had been coded as AF but were not in AF at the time of screening. Among the 19 at-risk screen-detected people with AF, 10 started appropriate anticoagulation therapy within 6 months. Of the nine patients who did not commence anticoagulation therapy, five had a subsequent adverse clinical outcome in the follow-up period, including one with ischaemic stroke; two had contraindications to anticoagulants. Among those with previously diagnosed AF, the proportion receiving anticoagulation therapy rose from 57% pre-screening to 83% at 6 months post-screening (p<0.0001); among newly diagnosed AF the proportion rose from 0% to 53% (p<0.01).
Conclusions: AF screening is a feasible low-cost adjunct to AAA screening with potential to reduce ethnic inequities in stroke incidence. However, effective measures are needed to ensure that high-risk newly diagnosed AF is managed according to best practice guidelines.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.hlc.2023.09.025 | DOI Listing |
J Enzyme Inhib Med Chem
December 2025
School of Life Sciences, Jinggangshan University, Ji'an, China.
Current antithrombotic therapies face dual constraints of bleeding complications and monitoring requirements. Although natural hirudin provides targeted thrombin inhibition, its clinical adoption is hindered by sourcing limitations. This study developed a recombinant hirudin variant HMg (rHMg) with enhanced anticoagulant activity through genetic engineering and established cost-effective large-scale production methods.
View Article and Find Full Text PDFJ Cardiothorac Vasc Anesth
August 2025
Goethe-University Frankfurt, University Hospital Frankfurt, Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Frankfurt, Germany; Department of Anesthesiology and Intensive Care Medicine, Rheinische Friedrich-Wilhelms-University, University Hospital Bonn, Bonn, Germany.
Objectives: To determine the incidence and subsequent complications of internal jugular vein (IJV) thrombosis after cannulation performed during cardiopulmonary bypass (CPB) to ensure adequate venous drainage during minimally invasive cardiac surgery.
Design: Single-center observational trial SETTINGS: Intensive care postoperative monitoring of cardiac surgery patients and diagnosis of IJV thrombi at a university tertiary hospital during the 13-month study period from December 1, 2022, to January 11, 2024.
Participants: 44 patients undergoing catheterization of the IJV for total CPB.
J Pediatr Surg
September 2025
Department of Pediatric Surgery, McGovern Medical School, UTHealth Houston and Children's Memorial Hermann Hospital, Houston, TX, USA(†). Electronic address:
Background: Repair strategies for pediatric vascular injuries must consider vascular growth and intervention durability. Endovascular interventions are increasingly utilized in pediatrics, particularly in unstable patients or for injuries in surgically morbid regions. This study describes a single-center experience with endovascular stenting in adolescent pediatric trauma.
View Article and Find Full Text PDFJ Pharm Pract
September 2025
Department of Pharmacy, Houston Methodist Hospital, TX, USA.
Critically ill adults are more commonly being admitted to intensive care units (ICU) with a recent history of direct oral anticoagulant (DOAC) use. No consensus guidance exists on optimal anticoagulation strategies in critically ill adults with non-valvular atrial fibrillation (NVAF) on DOAC's prior to ICU admission, and there is considerable variability in clinical practice. To evaluate rates of major bleeding and thrombosis between 2 anticoagulation strategies for NVAF upon ICU admission: package insert (continuation of oral or parenteral anticoagulation per manufacturer recommendations) vs non-package insert (prophylactic dosing or delayed therapeutic anticoagulation).
View Article and Find Full Text PDFCancer Immunol Immunother
September 2025
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).
View Article and Find Full Text PDF